Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(10): 636-637
DOI: 10.1055/a-1903-1752
Editorial

Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?

Stella Papachristou
1   Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
,
Manfredi Rizzo
2   Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy
,
Nikolaos Papanas
1   Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.

Key words

advanced glycation end products - bone formation - complications - diabetes mellitus


Publication History

Received: 11 June 2022
Received: 29 June 2022

Accepted: 07 July 2022

Article published online:
17 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ensrud KE, Ewing SK, Taylor BC. et al. Frailty and risk of falls, fracture, and mortality in older women: The study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 2007; 62: 744-751
    CrossrefPubMedGoogle Scholar
  • 2 Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am 2020; 104: 873-884
    CrossrefPubMedGoogle Scholar
  • 3 Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011; 12: 2096-2102
    CrossrefPubMedGoogle Scholar
  • 4 Papachristou S, Pafili K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord 2021; 21: 28
    CrossrefPubMedGoogle Scholar
  • 5 Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced glycation end-products (AGEs): Formation, chemistry, classification, receptors, and diseases related to AGEs. Cells 2022; 11: 1312
    CrossrefPubMedGoogle Scholar
  • 6 Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514-1523
    CrossrefPubMedGoogle Scholar
  • 7 Yang X, Liu CJ, Wang ZZ. et al. Effects of advanced glycation end products on osteocytes mechanosensitivity. Biochem Biophys Res Commun 2021; 568: 151-157
    CrossrefPubMedGoogle Scholar
  • 8 Jiang J, Zhao C, Han T. et al. Advanced glycation end products, bone health and diabetes mellitus. Exp Clin Endocrinol Diabetes. 2022 in press
    PubMedGoogle Scholar
  • 9 Zhou Z, Immel D, Xi CX. et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-1080
    CrossrefPubMedGoogle Scholar
  • 10 Stirban A, Heinemann L. Skin autofluorescence – a non-invasive measurement for assessing cardiovascular risk and risk of diabetes. Eur Endocrinol 2014; 10: 106-110
    CrossrefPubMedGoogle Scholar
  • 11 Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 527-533
    CrossrefPubMedGoogle Scholar
  • 12 Sanguineti R, Puddu A, Mach F. et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm 2014; 2014: 975872
    CrossrefPubMedGoogle Scholar
  • 13 Wang X, Zhao X, Lian T. et al. Skin autofluorescence and the complexity of complications in patients with type 2 diabetes mellitus: A cross-sectional study. BMC Endocr Disord 2021; 21: 58
    CrossrefPubMedGoogle Scholar
  • 14 Papachristou S, Pafili K, Trypsianis G. et al. Skin advanced glycation end products among subjects with type 2 diabetes mellitus with or without distal sensorimotor polyneuropathy. J Diabetes Res 2021; 2021: 6045677
    CrossrefPubMedGoogle Scholar
  • 15 Papachristou S, Pafili K, Trypsianis G. et al. Correlation between skin advanced glycation end products and cardiac autonomic neuropathy among subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2022; DOI: 10.1055/a-1831-0991. Epub ahead of print. PMID: 35451045
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Giglio RV, Stoian AP, Haluzik M. et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis 2021; 1867: 166148
    CrossrefPubMedGoogle Scholar